<DOC>
	<DOC>NCT01941771</DOC>
	<brief_summary>The study hypothesis is that metronomic treatment is more efficient than standard treatment.</brief_summary>
	<brief_title>Phase II Trial With Metronomic, Capecitabine Plus Oral Vinorelbine for Metastatic Breast Cancer</brief_title>
	<detailed_description>Purpose: In an open-label randomized phase II trial, patients with metastatic Human Epidermal Growth Factor Receptor 2-negative breast cancer with normal organ function sant WHO performance status &lt; 3 are randomized to receive either capecitabine (day 1-14) plus vinorelbine oral (day 1 and 8) or capecitabine (day 1-14) plus vinorelbine oral metronomic (3 days a week).</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Locally advanced or metastatic Human Epidermal Growth Factor Receptor2Negative breast cancer WHO performance status &lt; 3 Former treatment with Capecitabine or Vinorelbine Patients who have received more than one line of chemotherapy for metastatic disease Brain metastases Malabsorption syndrome Abnormal organ function pregnant or lactating women</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>Metronomic chemotherapy</keyword>
	<keyword>Vinorelbine</keyword>
	<keyword>Navelbine</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>Xeloda</keyword>
	<keyword>Antineoplastic Agents</keyword>
</DOC>